Cargando...
Sodium-glucose cotransporter inhibitors: beyond glycaemic control
Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium–glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated to reduce cardiovascular complications and slow diabetic kidney disease progression in patients with type 2 diabetes. The glycaemic control exer...
Gardado en:
| Publicado en: | Clin Kidney J |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6543973/ https://ncbi.nlm.nih.gov/pubmed/31198226 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfz019 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|